Clinical diabetes : a publication of the American Diabetes Association

How SNAC Helps the Body Absorb Oral Semaglutide

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Oral semaglutide, approved by the FDA in 2019, utilizes SNAC technology to enhance absorption in the gastrointestinal tract.

  • SNAC technology is designed to improve the absorption of peptide therapeutics in the stomach.
  • Oral semaglutide is a glucagon-like peptide 1 receptor agonist used for treating type 2 diabetes.
  • Studies indicate that coformulating SNAC with oral semaglutide may lead to increased absorption and bioavailability.
  • The article also includes practical advice for pharmacists regarding the dispensing of oral semaglutide.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Funding

Competing interests

C.S.-H. has served as a speaker for Novo Nordisk. M.P.K. has served as a member of a Novo Nordisk speaker’s bureau. C.T. has served as a speaker for Eli Lilly and Novo Nordisk and as a consultant for Bayer.
PubMed

Related papers

Jul '21
No QTc Heart Rhythm Changes with SNAC, an Absorption Helper Used with Oral Semaglutide
top 20% journal
cited by 2 papers
journal article
Dec '18
Safety and body processing of increasing doses of the new oral GLP-1 drug, semaglutide, in healthy people and those with type 2 diabetes
top 10% journal
cited by 153 papers
randomized controlled trial
Aug '19
Oral Semaglutide: Review of the First Pill That Mimics a Blood Sugar-Regulating Hormone
top 2% journal
cited by 126 papers
comparative study
Mar '21
How Oral Semaglutide Tablet Dissolving Affects Drug Absorption in the Body
cited by 28 papers
randomized controlled trial
Jul '22
Using SNAC to develop oral semaglutide for treating type 2 diabetes
top 5% journal
cited by 90 papers
research support, non-u.s. gov't
Dec '23
Development and testing of dissolvable stomach tablets for delivering a GIP/GLP1 peptide in monkeys
top 20% journal
cited by 15 papers
journal article
Aug '24
Making SNAC Phenolate Salts and Their Impact on How Well Semaglutide Is Absorbed When Taken by Mouth
top 20% journal
cited by 4 papers
journal article
Apr '19
How Oral Semaglutide Affects the Blood Levels of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy People
top 10% journal
cited by 50 papers
research support, non-u.s. gov't
Dec '21
Oral semaglutide, the first GLP-1 medicine taken by mouth (Rybelsus®)
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 days ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
1 week ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
2 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
3 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
4 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
5 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
6 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
7 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
9 weeks ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief